[
    [
        {
            "time": "",
            "original_text": "贝达药业港股上市审核状态标注“失效” 回应称“正常推进中”",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港股",
                    "上市",
                    "审核",
                    "失效",
                    "正常推进"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业港股上市审核状态标注“失效” 回应称“正常推进中”",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）：拟推1555万股2021年限制性股票激励计划",
            "features": {
                "keywords": [
                    "贝达药业",
                    "限制性股票",
                    "激励计划",
                    "2021年"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）：拟推1555万股2021年限制性股票激励计划",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）提名范建勋为非独立董事候选人",
            "features": {
                "keywords": [
                    "贝达药业",
                    "非独立董事",
                    "范建勋",
                    "提名"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）提名范建勋为非独立董事候选人",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）拟推出2021年限制性股票激励计划 授予价为41.34元/股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "限制性股票",
                    "激励计划",
                    "授予价",
                    "41.34元/股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）拟推出2021年限制性股票激励计划 授予价为41.34元/股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：拟向激励对象468人授予限制性股票1555万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "激励对象",
                    "限制性股票",
                    "1555万股",
                    "468人"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：拟向激励对象468人授予限制性股票1555万股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业FGFR4 抑制剂BPI-43487项目I期临床研究首例受试者入组",
            "features": {
                "keywords": [
                    "贝达药业",
                    "FGFR4抑制剂",
                    "BPI-43487",
                    "临床研究",
                    "首例受试者入组"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业FGFR4 抑制剂BPI-43487项目I期临床研究首例受试者入组",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]